Jasper Therapeutics (JSPR) Change in Account Payables (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Change in Account Payables of -$2.9 million for Q4 2025, down 407.84% year-over-year from $957000.0 in Q4 2024, and down 360.25% quarter-over-quarter from $1.1 million in Q3 2025.
Jasper Therapeutics (JSPR) Change in Account Payables (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Change in Account Payables history runs 6 years deep, the most recent figure standing at -$2.9 million for Q4 2025.
- In Q4 2025, Change in Account Payables fell 407.84% year-over-year to -$2.9 million; the TTM figure through Dec 2025 stood at $2.2 million (up 1897.54% YoY), while the FY2025 annual figure was $2.2 million, up 1897.54% from the prior year.
- Change in Account Payables for Q4 2025 stood at -$2.9 million, down from $1.1 million in the prior quarter.
- The five-year high for Change in Account Payables was $5.0 million in Q2 2025, with the low at -$2.9 million in Q4 2025.
- The 5-year median for Change in Account Payables is $339500.0 (2024), against an average of $261950.0.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables sank 3055.42% in 2022, then surged 1004.16% in 2025.
- Jasper Therapeutics' Change in Account Payables stood at $1.7 million in 2021, then sank by 178.52% to -$1.3 million in 2022, then surged by 166.2% to $893000.0 in 2023, then gained by 7.17% to $957000.0 in 2024, then plunged by 407.84% to -$2.9 million in 2025.
- Business Quant data shows JSPR's Change in Account Payables at -$2.9 million in Q4 2025, $1.1 million in Q3 2025, and $5.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.95 Mn |
| Dec 31, 2025 | -2.95 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Mar 31, 2025 | -1.04 Mn |
| Mar 31, 2025 | -1.04 Mn |
| Dec 31, 2024 | 957,000.00 |
| Dec 31, 2024 | 957,000.00 |
| Sep 30, 2024 | 222,000.00 |
| Sep 30, 2024 | 222,000.00 |
| Jun 30, 2024 | 457,000.00 |
| Jun 30, 2024 | 457,000.00 |
| Mar 31, 2024 | -1.76 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | 893,000.00 |
| Dec 31, 2023 | 893,000.00 |
| Sep 30, 2023 | 1.68 Mn |
| Sep 30, 2023 | 1.68 Mn |